WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
WuXi XDC Included in MSCI China All Share Index
(Shanghai, China, August 8, 2025) – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the...WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity
（Wuxi, China, August 5, 2025）- WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 (“DP3”)...WuXi XDC 2025 Interim Results and Corporate Update Call
Dear Investors & Analysts, WuXi XDC cordially invites you to join our 2025 Interim Results and Corporate Update Call. Please scan the QR codes or through direct link to register and participate the calls: · CN Earnings Call Date / Time： 19 August...WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
Shanghai, China, and Singapore June 30, 2025 WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that...WuXi XDC Received Multiple Awards from 2025 Extel (previously “Institutional Investor”) Ranking in Diverse Categories
Shanghai, China, May 20, 2025 WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?